Comparing the impact of dienogest with short term gonadotropin-releasing hormone (GnRH) analogue usage in endometriosis prior to laparoscopic cystectomy.

Submission date	Recruitment status No longer recruiting	Prospectively registered		
31/05/2016		☐ Protocol		
Registration date	Overall study status Completed Condition category	Statistical analysis plan		
27/07/2016		Results		
Last Edited		Individual participant data		
29/07/2016	Urological and Genital Diseases	Record updated in last year		

Plain English summary of protocol

Background and study aims

Endometriosis is a common medical condition where tissue that behaves like that found in the womb (the endometrium) can be found outside of the womb. These pieces of tissue can be found in many different areas of the body, including, for example, the ovaries and fallopian tubes, the bowel and the bladder. Endometriosis is a debilitating disease, which can cause a chronic (long lasting) and unbearable pelvic pain. 10-15% of women of reproductive age group suffer from pelvic endometriosis and 50% of infertile women is said to be suffering from endometriosis. Treatment include medical and surgical interventions aiming to alleviate these symptoms and to improve fertility rate. Drug therapy includes pain killers, gonadotrophinreleasing hormone (GnRH) analogues, progestin and now, dienogest. GnRH will cause a state of hypoestrogenemia (a menopause-like state) which lead to an easing of the pain suffered. However, although it is an effective treatment, its prolonged used is associated with significant symptoms of hypoestrogenism (for example, hot flashes, headaches, lower than usual sex drive), and decreased bone mineral density, which could lead to brittle bones (secondary osteoporosis). Dienogest in the other hand is a 4th generation selective progestin. It stops ovulation, and prevents the lining of the womb and any endometriosis tissue outside of the womb from growing quickly. Surgery can be used to remove endometriosis tissue. The gold standard is laparoscopic cystectomy. However, the side effects of this surgery has been questioned. Although it does reduce the risk of recurrence, it is associated with removal of ovarian tissue together with the wall, leading to a loss of follicles and postsurgical ovarian failure (3%). The aim of this study is to investigate the result of a combined medical and surgical treatment for endometriosis.

Who can participate?

Women with endometriosis with a cyst that is to be removed via a laparoscopic cystectomy.

What does the study involve?

Participants are randomly allocated to one of three groups. Those on group 1 are not given any

treatment prior to a laparoscopic cystectomy. Those in group 2 are given a single dose of a GnRH analogue 1 month before surgery. Those in group 3 are given dienogest once a day for 30 days before undergoing surgery. After the surgery, all participants are assessed to determine the success of the treatment and their overall satisfaction of the care they receive.

What are the possible benefits and risks of participating?

They may be no direct benefits to taking part in the study, but the results may help improve the treatment or management of the condition for other patients. Possible side effects include nausea, vomiting, breast engorgement, irregular menstrual bleed, abdominal cramps, flatulence, sleep disorder, loss of libido (sex drive), altered mood and migraine headaches.

Where is the study run from?
University Malaya Medical Centre (Malaysia)

When is the study starting and how long is it expected to run for? June 2016 to June 2017

Who is funding the study? University Malaya Medical Centre (Malaysia)

Who is the main contact? Dr Aizura Syafinaz Ahmad Adlan

Contact information

Type(s)

Scientific

Contact name

Dr Aizura Syafinaz Ahmad Adlan

Contact details

104, SS22/2 Damansara Jaya Petaling Jaya Malaysia 47400

Additional identifiers

Protocol serial number

NMRR-16-317-29736

Study information

Scientific Title

Comparing the impact of Dienogest with short term GnRH analogue usage in women with Endometriosis prior to laparoscopic Cystectomy: a randomised controlled trial

Acronym

Study objectives

Preoperative usage of dienogest will give better surgical outcomes compared to preoperative GnRH usage, for women undergoing laparoscopic cystectomy for endometriomas.

Ethics approval required

Old ethics approval format

Ethics approval(s)

University of Malaya Medical Centre Medical Ethics Committee, 18/01/2016, ref: MECID.NO: 20159-1645

Study design

Interventional randomised controlled trial, single centre.

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Endometriosis

Interventions

Prior to the initiation of the study, blood will be taken for series of investigations- for AMH, Ca 125, FSH/LH level. Transvaginal ultrasound will be performed to look for antral follicular count.

Participants are allocated into one of three groups:

Group 1: No pretreatment administered pre-operatively (control group)

Group 2: single dose of GnRH analogue will be given (s/c lucrin 3.75mg) 1 month prior to the surgery date

Group 3: oral dienogest 2mg daily will be given to be taken for 30 days

A laparoscopic cystectomy will be performed 1 month after the initiation of the above treatment. After the operation all participants are also assessed regarding overall satisfaction of the treatment that they have received.

Randomisation is made by computerised block randomisation. Patient will pick 1 out of 3 sealed envelope the patient is not blinded by the treatment that they will receive, the surgeon however will not be made aware of the treatment received by their patient.

Intervention Type

Supplement

Primary outcome(s)

- 1. Feasibility of cyst extraction intraoperatively (rating: easy/moderate/difficult)
- 2. Duration of surgery (recorded in minutes)
- 2. Patient satisfaction with the post operative pain relief using a visual analogue score

Key secondary outcome(s))

Intraoperative blood loss in millilitres. Outcome will be retrieved from the surgical notes, anaesthetists notes on or after hospital discharge.

Completion date

30/06/2017

Eligibility

Key inclusion criteria

- 1. Patients with cyst suspicious of endometrioma
- 2. Cyst measures > 4 cm
- 3. Planned for a laparoscopic cystectomy

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Female

Key exclusion criteria

Patients with cysts suspicious of malignancy.

Date of first enrolment

01/06/2016

Date of final enrolment

30/06/2017

Locations

Countries of recruitment

Malaysia

Study participating centre University Malaya Medical Centre

Lembah Pantai Kuala Lumpur Malaysia 50603

Sponsor information

Organisation

University Malaya Medical Centre, University of Malaya.

ROR

https://ror.org/00vkrxq08

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

University Malaya Medical Centre

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet		22/07/2016	29/07/2016	No	Yes
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes